Is Avadel Pharmaceuticals PLC (AVDL) overvalued? · rev $169.1M
Avadel Pharmaceuticals PLC (AVDL) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Avadel Pharmaceuticals PLC (AVDL) looks expensive on cached numbers — not a short thesis.
Latest reported AVDL revenue for 2024-12-31 was $169.1M. Net income was -$48.8M. Revenue was up 504.8% from 2023-12-31 to 2024-12-31. AVDL currently screens at market cap $968.5M.
AVDL currently screens at market cap $968.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AVDL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AVDL stock page for the full model, not this heading.
Not investment advice.